Visfatin mediates doxorubicin resistance in human non–small‐cell lung cancer <i>via</i> Akt‐mediated up‐regulation of <scp>ABCC</scp>1

Abstract

These data showed that visfatin can decrease Dox sensitivity of NSCLC cells via activation of Akt/MRP1. It indicated that inhibition of visfatin signals might be a promising therapeutic strategy for the management of chemoresistance of NSCLC patients.